Evidence map›Paper›PMID 28969385›Full record

ArticleBrain : a journal of neurology2017

Mutations of AKT3 are associated with a wide spectrum of developmental disorders including extreme megalencephaly.

Diana Alcantara, Andrew E Timms, Karen Gripp, Laura Baker, Kaylee Park, Sarah Collins, Chi Cheng, Fiona Stewart, Sarju G Mehta, Anand Saggar and 23 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Frontiers in neurology · 2024
    Article
  18. MYCN in human development and diseases.Frontiers in oncology · 2024
    Review
  19. Review
  20. [Update on nevi and nevoid skin disorders].Dermatologie (Heidelberg, Germany) · 2023
    Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 19 institutions in 8 countries.

Diana AlcantaraGenome Damage and Stability Centre, University of Sussex, Sussex, UK.
Andrew E TimmsCenter for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA, USA.
Karen GrippDepartment of Pediatrics, Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Laura BakerDepartment of Pediatrics, Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Kaylee ParkCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Sarah CollinsCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Chi ChengCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Fiona StewartBelfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Sarju G MehtaEast Anglian Medical Genetics Service, Addenbrookes Hospital, Cambridge, UK.
Anand SaggarSouth West Thames Regional Genetic Services, St. George's NHS Trust and St. George's Hospital Medical School, London, UK.
László SztrihaDepartment of Pediatrics, University of Szeged, Szeged, Hungary.
Melinda ZomborDepartment of Pediatrics, University of Szeged, Szeged, Hungary.
Oana CaluseriuDepartment of Medical Genetics, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Ronit MestermanDivision of Pediatric Neurology, Developmental Pediatric Rehabilitation and Autism Spectrum Disorder, McMaster University, Hamilton, ON, Canada.
Margot I Van AllenDepartment of Medical Genetics, University of British Columbia, Vancouver, Canada.
Adeline JacquinetCenter for Human Genetics, Centre Hospitalier Universitaire and University of Liège, Liège, Belgium.
Sofia YgbergNeuropediatric Unit and Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital, Stockholm, Sweden.
Jonathan A BernsteinDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Aaron M WengerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Harendra GuturuDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Gill BejeranoDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Natalia Gomez-OspinaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Anna LehmanDepartment of Medical Genetics, University of British Columbia, Vancouver, Canada.
Enrico AlfeiDevelopmental Neurology Unit, Department of Pediatric Neurosciences, Carlo Besta Neurological Institute, IRCCS Foundation, Milan, Italy.
Chiara PantaleoniDevelopmental Neurology Unit, Department of Pediatric Neurosciences, Carlo Besta Neurological Institute, IRCCS Foundation, Milan, Italy.
Valerio ContiPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.
Renzo GuerriniPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.
Ute MoogInstitute of Human Genetics, Heidelberg University, Heidelberg, Germany.
John M GrahamDepartment of Pediatrics, Cedars-Sinai Medical Center, Harbor-UCLA Medical Center, David Geffen School of Medicine Los Angeles, California, USA.
Robert HevnerCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
William B DobynsCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Mark O'DriscollGenome Damage and Stability Centre, University of Sussex, Sussex, UK.
Ghayda M MirzaaCenter for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Stanford University · USUniversity of Washington · USFondazione IRCCS Istituto Neurologico Carlo Besta · ITThomas Jefferson University · USUniversity of British Columbia · CAUniversity of Sussex · GBUniversity of Szeged · HUAddenbrooke's Hospital · GBBelfast Health and Social Care Trust · GBCedars-Sinai Medical Center · USCentre Hospitalier Universitaire de Liège · BEHeidelberg University · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska University Hospital · SEMcMaster University · CAMeyer Children's Hospital · ITSeattle Children's Hospital · USSt George's Hospital · GBUniversity of Alberta · CA

Funding

GENETICS TRAINING PROGRAM FOR PHD CANDIDATEST32GM007790 · NIGMS · STANFORD UNIVERSITY · PI BRUNET, ANNE, KINGSLEY, DAVID M · 1985 to 2020
$12.8M
Intellectual and Developmental Disabilities Research CenterU54HD083091 · NICHD · UNIVERSITY OF WASHINGTON · PI DOHERTY, DANIEL · 2014 to 2019
$7.9M
Megalencephaly and segmental brain overgrowth in humansR01NS092772 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI MILLEN, KATHLEEN JOYCE · 2015 to 2019
$3.3M
Genes and pathways underlying brain overgrowth and focal cortical malformationsK08NS092898 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI MIRZAA, GHAYDA · 2015 to 2019
$930k
Cancer Research UK 15394NICHD NIH HHS U54 HD083091NIGMS NIH HHS T32 GM007790NINDS NIH HHS K08 NS092898NINDS NIH HHS R01 NS092772
6 · The paper itself

Abstract

Mutations of genes within the phosphatidylinositol-3-kinase (PI3K)-AKT-MTOR pathway are well known causes of brain overgrowth (megalencephaly) as well as segmental cortical dysplasia (such as hemimegalencephaly, focal cortical dysplasia and polymicrogyria). Mutations of the AKT3 gene have been reported in a few individuals with brain malformations, to date. Therefore, our understanding regarding the clinical and molecular spectrum associated with mutations of this critical gene is limited, with no clear genotype-phenotype correlations. We sought to further delineate this spectrum, study levels of mosaicism and identify genotype-phenotype correlations of AKT3-related disorders. We performed targeted sequencing of AKT3 on individuals with these phenotypes by molecular inversion probes and/or Sanger sequencing to determine the type and level of mosaicism of mutations. We analysed all clinical and brain imaging data of mutation-positive individuals including neuropathological analysis in one instance. We performed ex vivo kinase assays on AKT3 engineered with the patient mutations and examined the phospholipid binding profile of pleckstrin homology domain localizing mutations. We identified 14 new individuals with AKT3 mutations with several phenotypes dependent on the type of mutation and level of mosaicism. Our comprehensive clinical characterization, and review of all previously published patients, broadly segregates individuals with AKT3 mutations into two groups: patients with highly asymmetric cortical dysplasia caused by the common p.E17K mutation, and patients with constitutional AKT3 mutations exhibiting more variable phenotypes including bilateral cortical malformations, polymicrogyria, periventricular nodular heterotopia and diffuse megalencephaly without cortical dysplasia. All mutations increased kinase activity, and pleckstrin homology domain mutants exhibited enhanced phospholipid binding. Overall, our study shows that activating mutations of the critical AKT3 gene are associated with a wide spectrum of brain involvement ranging from focal or segmental brain malformations (such as hemimegalencephaly and polymicrogyria) predominantly due to mosaic AKT3 mutations, to diffuse bilateral cortical malformations, megalencephaly and heterotopia due to constitutional AKT3 mutations. We also provide the first detailed neuropathological examination of a child with extreme megalencephaly due to a constitutional AKT3 mutation. This child has one of the largest documented paediatric brain sizes, to our knowledge. Finally, our data show that constitutional AKT3 mutations are associated with megalencephaly, with or without autism, similar to PTEN-related disorders. Recognition of this broad clinical and molecular spectrum of AKT3 mutations is important for providing early diagnosis and appropriate management of affected individuals, and will facilitate targeted design of future human clinical trials using PI3K-AKT pathway inhibitors.

Indexed as

BrainChildDevelopmental DisabilitiesFemaleGenetic Association StudiesHEK293 CellsHumansImmunoprecipitationMagnetic Resonance ImagingMaleMegalencephalyMutagenesis, Site-DirectedMutationPhosphatidylinositolsProto-Oncogene Proteins c-aktTransfectionAKT3 protein, humanPhosphatidylinositolsProto-Oncogene Proteins c-aktAKT3epilepsyhemimegalencephalymegalencephalypolymicrogyria

Identifiers

PMID28969385
PMCPMC6080423
OpenAlexW2750721430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.